Download PDF
Thromb Haemost 1999; 82(02): 209-217
DOI: 10.1055/s-0037-1615835
Research Article
Schattauer GmbH

Factor VIII-Factor IX Interactions: Molecular Sites Involved in Enzyme-Cofactor Complex Assembly

Koen Mertens
1   Departments of Plasma Protein Technology and Blood Coagulation, CLB, Amsterdam, THE NETHERLANDS
,
Patrick H.N. Celie
1   Departments of Plasma Protein Technology and Blood Coagulation, CLB, Amsterdam, THE NETHERLANDS
,
Joost A. Kolkman
1   Departments of Plasma Protein Technology and Blood Coagulation, CLB, Amsterdam, THE NETHERLANDS
,
Peter J. Lenting
1   Departments of Plasma Protein Technology and Blood Coagulation, CLB, Amsterdam, THE NETHERLANDS
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

The activation of factor X is one of the steps in the coagulation cascade that is driven by the assembly of an activated serine protease with a membrane-bound cofactor. In the initial phase of coagulation, factor X is activated by the complex of activated factor VII (factor VIIa) and tissue factor. Subsequently, during the so-called propagation phase, factor X activation is catalyzed by the complex of activated factor IX (factor IXa) and activated factor VIII (factor VIIIa). In these complexes, factor VIIa and factor IXa are the factor X-activating enzymes, whereas tissue factor and factor VIIIa serve as non-enzymatic cofactors.1 Factors VIIa and IXa are highly homologous to other cofactor-dependent enzymes, such as activated factor X (factor Xa) and activated protein C, both in amino acid sequence, domain organization, and three-dimensional structure.2 Factor VIIa and IXa further share low or negligible activity towards their natural substrate factor X, unless in complex with their physiological cofactors.

Although tissue factor and factor VIIIa serve similar roles as biological amplifiers, they are structurally different. Tissue factor is a small, transmembrane protein with an extracellular part comprising 219 amino acids. Factor VIII is much larger (2,332 amino acids), circulates in plasma, and requires proteolytic processing to exert its biological activity.3 When cofactors are assembled with their respective enzymes, a dramatic increase in enzymatic activity occurs. The underlying molecular mechanism, however, remains poorly understood.

During the past few years, remarkable progress has been made in understanding the molecular details of enzyme-cofactor assembly within the coagulation cascade. Crystallography has provided high-resolution structures of tissue factor4 and the various cofactor-dependent coagulation enzymes.2 Moreover, the crystal structure of the factor VIIa—tissue factor complex has been resolved and has allowed the identification of the molecular sites involved in enzyme-cofactor interaction.5,6 Such details are still lacking, however, for the factor IXa—factor VIIIa complex. Current views are derived from three-dimensional models generated by homology modeling based on structurally-related proteins, such as nitrite reductase,7 ceruloplasmin,8 and galactose oxidase.9 Despite their inherent limitations, these models greatly facilitate the interpretation of previous functional studies on factor X activation. As such, the availability of molecular models may be considered an important step toward resolving the structure of the factor IXa—factor VIIIa complex and understanding the role of complex assembly and defects thereof. This chapter provides an overview of the current developments in this field.

 

  • References

  • 1 Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
    PubMedGoogle Scholar
  • 2 Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost. 1997; 78: 501-511.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
    PubMedGoogle Scholar
  • 4 Harlos K, Martin DMA, O’Brien DP, Jones EY, Stuart DI, Polikarpov I, Miller A, Tuddenham EGD, Boys CWG. Crystal structure of the extracellular region of human tissue factor. Nature 1994; 370: 662-666.
    CrossrefPubMedGoogle Scholar
  • 5 Banner DW, D’Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
    CrossrefPubMedGoogle Scholar
  • 6 Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF:VIIa complex in the cellular initiation of coagulation. Thromb Haemost. 1997; 78: 401-405.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Pan Y, DeFay T, Gitschier J, Cohen FE. Proposed structure of the A domains of factor VIII by homology modelling. Nat Struct Biol. 1995; 2: 740-744.
    CrossrefPubMedGoogle Scholar
  • 8 Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-2421.
    PubMedGoogle Scholar
  • 9 Pellequer J-L, Gale AJ, Griffin JH, Getzoff ED. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. Blood Cells Mol Dis. 1998; 24: 448-461.
    CrossrefPubMedGoogle Scholar
  • 10 Macfarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-499.
    CrossrefPubMedGoogle Scholar
  • 11 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312.
    CrossrefPubMedGoogle Scholar
  • 12 Van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981; 256: 3433-3442.
    PubMedGoogle Scholar
  • 13 Mertens K, Bertina RM. The contribution of Ca2+ and phospholipids to the activation of human blood coagulation factor X by activated factor IX. Biochem J. 1984; 223: 607-615.
    CrossrefPubMedGoogle Scholar
  • 14 Mertens K, Van Wijngaarden A, Bertina RM. The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemost. 1985; 54: 654-660.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988; 53: 505-518.
    CrossrefPubMedGoogle Scholar
  • 16 Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA. 1995; 92: 9796-9800.
    CrossrefPubMedGoogle Scholar
  • 17 Wood WI, Capon DJ, Simonson CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337
    CrossrefPubMedGoogle Scholar
  • 18 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342.
    CrossrefPubMedGoogle Scholar
  • 19 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Bueker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
    CrossrefPubMedGoogle Scholar
  • 20 Church WR, Jernigan RL, Toole J, Hewick RM, Knopf J, Knutson GJ, Nesheim ME, Mann KG, Fass DN. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci USA. 1984; 81: 6934-6937.
    CrossrefPubMedGoogle Scholar
  • 21 Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost. 1998; 79: 1068-1079.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Mertens K, Cupers R, Van Wijngaarden A, Bertina RM. Binding of human blood coagulation factors IXa and X to phospholipid membranes. Biochem J. 1984; 223: 599-605.
    CrossrefPubMedGoogle Scholar
  • 23 Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem. 1996; 271: 16227-16236.
    CrossrefPubMedGoogle Scholar
  • 24 Ahmad SS, Wong MY, Rawala R, Jameson BA, Walsh PN. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry. 1998; 37: 1671-1679.
    CrossrefPubMedGoogle Scholar
  • 25 Cheung WF, Van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA. 1996; 93: 11068-11073.
    CrossrefPubMedGoogle Scholar
  • 26 Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. J Biol Chem. 1992; 267: 17012-17021.
    PubMedGoogle Scholar
  • 27 Stoylova S, Gray E, Barrowcliffe TW, Kemball-Cook G, Holzenburg A. Structural determination of lipid-bound human blood coagulation factor IX. Biochim Biophys Acta. 1998; 1383: 175-178.
    CrossrefPubMedGoogle Scholar
  • 28 Gilbert GE, Drinkwater D, Barter S, Clouse SB. Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. J Biol Chem. 1992; 267: 15861-15868.
    PubMedGoogle Scholar
  • 29 Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipids. J Biol Chem. 1990; 265: 815-822.
    PubMedGoogle Scholar
  • 30 Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry. 1993; 32: 9577-9585.
    CrossrefPubMedGoogle Scholar
  • 31 Spaargaren J, Giessen PLA, Janssen MP, Voorberg J, Willems GM, van Mourik JA. Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. Biochem J. 1995; 310: 539-545.
    CrossrefPubMedGoogle Scholar
  • 32 Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidyl serine. Blood 1990; 75: 1999-2004.
    PubMedGoogle Scholar
  • 33 Lenting PJ, Donath MJSH, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994; 269: 7150-7155.
    PubMedGoogle Scholar
  • 34 O’Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem. 1995; 270: 27087-27092.
    CrossrefPubMedGoogle Scholar
  • 35 Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998; 273: 19049-19054.
    CrossrefPubMedGoogle Scholar
  • 36 Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem. 1997; 272: 2082-2088.
    CrossrefPubMedGoogle Scholar
  • 37 Lapan KA, Fay PJ. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost. 1998; 80: 418-422.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Lenting PJ, ter Maat H, Clijsters PPFM, Donath MJSH, van Mourik JA, Mertens K. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J Biol Chem. 1995; 270: 14884-14890.
    CrossrefPubMedGoogle Scholar
  • 39 Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem. 1988; 263: 10451-10455.
    PubMedGoogle Scholar
  • 40 Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood coagulation factor VIII and von Willebrand factor. Biochem J. 1989; 257: 679-683.
    CrossrefPubMedGoogle Scholar
  • 41 Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem. 1997; 272: 18007-18014.
    CrossrefPubMedGoogle Scholar
  • 42 Andersson LO, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J. 1981; 200: 161-167.
    CrossrefPubMedGoogle Scholar
  • 43 Laimanovich A, Hudry-Clergeon G, Freyssinet J-M, Marguerie G. Human factor VIII procoagulant activity and phospholipid interaction. Biochim Biophys Acta. 1981; 678: 132-136.
    CrossrefPubMedGoogle Scholar
  • 44 Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem. 1995; 270: 13826-13833.
    CrossrefPubMedGoogle Scholar
  • 45 Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem. 1998; 273: 27918-27926.
    CrossrefPubMedGoogle Scholar
  • 46 Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem. 1992; 267: 17006-17011.
    PubMedGoogle Scholar
  • 47 Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem. 1992; 267: 3725-3730.
    PubMedGoogle Scholar
  • 48 Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994; 269: 20522-20527.
    PubMedGoogle Scholar
  • 49 Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem. 1996; 271: 11120-11125.
    CrossrefPubMedGoogle Scholar
  • 50 Mathur A, Zhong D, Sabharwal AK, Smith KJ, Bajaj SP. Interaction of factor IXa with factor VIIIa. J Biol Chem. 1997; 272: 23418-23426.
    CrossrefPubMedGoogle Scholar
  • 51 Jorquera JI, McClintock RA, Roberts JR, MacDonald MJ, Houghten RA, Fulcher CA. Synthetic peptides derived from residues 698 to 710 of factor VIII inhibit factor IXa activity. Circulation. 1992; 86: 685a.
    PubMedGoogle Scholar
  • 52 Celie PHN, Donath MJSH, Jorieux S, van Mourik JA, Mazurier C, Mertens K. Characterization of Arg527 and Arg531 substitution variants of factor VIII associated with mild haemophilia. Thromb Haemost. 1997; 77 (Suppl) 570a.
    PubMedGoogle Scholar
  • 53 Kemball-Cook G, Tuddenham EGD. The factor VIII mutation database on the world wide web: the haemophilia A mutation, search, test and resource site. Hamsters update (version 3.0, http://europium.mrc.rpms.ac.uk). Nucl Acid Res. 1997; 25: 128-132.
    CrossrefPubMedGoogle Scholar
  • 54 Amano K, Sarkar R, Pemberton S, Kemball-Cook G, Kazazian HH, Kaufman RJ. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91: 538-548.
    PubMedGoogle Scholar
  • 55 Liles DK, Monroe DM, Roberts HR. The factor VIII peptide consisting of amino acids 698 to 712 enhances factor IXa cleavage of factor X. Blood 1997; 90 (Suppl. 01) 463a.
    PubMedGoogle Scholar
  • 56 Mertens K, van Wijngaarden A, Bertina RM, Veltkamp JJ. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII. Thromb Haemost. 1985; 54: 650-653.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Pieneman WC, Fay PJ, Briët E, Reitsma PH, Bertina RM. Partial reconstitution of factor VIII activity from a mild CRM+ hemophilia A patient by replacement of the defective A2 domain. Thromb Haemost. 1998; 79: 943-948.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor-VIII interactive sites involved in stimulation of enzyme activity. Biochem J. 1999; 339: 217-221.
    PubMedGoogle Scholar
  • 59 Chang J, Jin J, Lollar P, Bode W, Brandstetter H, Hamaguchi N, Straight DL, Stafford DW. Changing residue 338 in human factor IX from Arginine to Alanine causes an increase in catalytic activity. J Biol Chem. 1998; 273: 12089-12094.
    CrossrefPubMedGoogle Scholar
  • 60 Mathur A, Zhong D, Smith KJ, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Blood 1998; 92: 252a-253a.
    PubMedGoogle Scholar
  • 61 Chang JL, Lin JP, Straight DL, Stafford DW. Residues 330-338 in catalytic domain of factor IX represent an interactive site for both factor VIIIa and factor X. Blood 1998; 92: 184a.
    PubMedGoogle Scholar
  • 62 Lenting PJ, van de Loo JWHP, Donath MJSH, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996; 271: 1935-1940.
    CrossrefPubMedGoogle Scholar
  • 63 Fijnvandraat K, Celie PHN, Turenhout E, ten Cate JW, van Mourik JA, Mertens K, Peters M, Voorberg J. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998; 91: 2347-2352.
    PubMedGoogle Scholar
  • 64 Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-142.
    PubMedGoogle Scholar
  • 65 Lenting PJ, Christophe OD, ter Maat H, Rees DJG, Mertens K. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem. 1996; 271: 25332-25337.
    CrossrefPubMedGoogle Scholar
  • 66 Christophe OD, Lenting PJ, Kolkman JA, Brownlee GG, Mertens K. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. J Biol Chem. 1998; 273: 222-227.
    CrossrefPubMedGoogle Scholar
  • 67 Lin SW, Smith KJ, Welsch D, Stafford DW. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem. 1990; 265: 144-150.
    PubMedGoogle Scholar
  • 68 Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest. 1997; 100: 886-892.
    CrossrefPubMedGoogle Scholar
  • 69 Larson PJ, Stanfield-Oakly S, van Dusen WJ, Kasper CK, Smith KJ, Monroe DM, High KA. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa. J Biol Chem. 1996; 271: 3869-3876.
    CrossrefPubMedGoogle Scholar
  • 70 Hughes PE, Morgan G, Rooney EK, Brownlee GG, Handford PA. Tyrosine 69 of the first epidermal growth factor-like domain of human factor IX is essential for clotting activity. J Biol Chem. 1993; 268: 17727-17773.
    PubMedGoogle Scholar
  • 71 Nishimura H, Takeya H, Miyata T, Suehiro K, Okamura T, Niho Y, Iwanaga S. Factor IX Fukuoka: substitution of Asn92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIIa/X. J Biol Chem. 1993; 268: 24041-24046.
    PubMedGoogle Scholar